Anti Asthma Drugs Companies

GlaxoSmithKline (GSK) acquired Innoviva, a biopharmaceutical company specializing in respiratory diseases, for $2.9 billion. This deal strengthens GSK's position in the asthma market with Innoviva's leading biologic drug, Mepolizumab (Nucala).

AstraZeneca is reportedly in talks to acquire Cinfa Laboratories, a Spanish generics company with a strong presence in Europe's asthma medication market. This move could potentially expand AstraZeneca's reach and affordability of its asthma drugs.

Sanofi received FDA approval for Dupixent (dupilumab) as an add-on maintenance therapy for children aged 6 to 11 years with severe asthma with type 2 inflammation. This expands the market reach of Dupixent, a major revenue driver for Sanofi.

Teva Pharmaceuticals launched QVAR AeroChamber Plus, a combination inhaler for asthma control, featuring an improved delivery system and reduced environmental impact. This launch strengthens Teva's position in the quick-relief medication segment.

Regeneron Pharmaceuticals announced positive Phase 3 trial results for REGN4210, a novel IL-33 antagonist, showing significant improvements in lung function and symptom control in patients with severe asthma. This could lead to a new treatment option in the near future.

Novartis is conducting Phase 2b trials for SB249999, a JAK1 inhibitor, for the treatment of moderate-to-severe asthma. JAK1 inhibitors are seen as promising alternatives to existing biologic therapies due to their potential for oral administration.

• GlaxoSmithKline plc.


• Merck & Co., Inc.


• AstraZeneca plc.


• Hoffmann-La Roche Ltd


• Teva Pharmaceutical Industries


• Innoviva, Inc.


• Novartis International AG


• Boehringer Ingelheim


• Chiesi Farmaceutici S.p.A.


• Sunovion Pharmaceuticals Inc.